EA202192289A1 - Способы мечения эукариотных клеток многоклеточного организма, а также лечения и/или диагностики рака с использованием модифицированных моносахаридных соединений - Google Patents

Способы мечения эукариотных клеток многоклеточного организма, а также лечения и/или диагностики рака с использованием модифицированных моносахаридных соединений

Info

Publication number
EA202192289A1
EA202192289A1 EA202192289A EA202192289A EA202192289A1 EA 202192289 A1 EA202192289 A1 EA 202192289A1 EA 202192289 A EA202192289 A EA 202192289A EA 202192289 A EA202192289 A EA 202192289A EA 202192289 A1 EA202192289 A1 EA 202192289A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
cancer
cells
eurariotic
tagging
Prior art date
Application number
EA202192289A
Other languages
English (en)
Inventor
Сам ДЮКАН
Original Assignee
Диамидекс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Диамидекс filed Critical Диамидекс
Publication of EA202192289A1 publication Critical patent/EA202192289A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/02—Monosaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к модифицированным моносахаридным соединениям, применяемым в способах мечения и/или обнаружения эукариотической клетки многоклеточного организма. Изобретение также относится к таким модифицированным моносахаридным соединениям, применяемым в способах идентификации или выделения раковых клеток, диагностики рака или для клеточной терапии.
EA202192289A 2019-02-20 2020-02-20 Способы мечения эукариотных клеток многоклеточного организма, а также лечения и/или диагностики рака с использованием модифицированных моносахаридных соединений EA202192289A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305202 2019-02-20
PCT/EP2020/054567 WO2020169782A1 (en) 2019-02-20 2020-02-20 Methods for labeling eukaryotic cells from a multicellular organism as well as for treating and/or diagnosing a cancer using modified monosaccharide compounds

Publications (1)

Publication Number Publication Date
EA202192289A1 true EA202192289A1 (ru) 2021-11-17

Family

ID=65766918

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192289A EA202192289A1 (ru) 2019-02-20 2020-02-20 Способы мечения эукариотных клеток многоклеточного организма, а также лечения и/или диагностики рака с использованием модифицированных моносахаридных соединений

Country Status (15)

Country Link
US (1) US20220146516A1 (ru)
EP (1) EP3928097A1 (ru)
JP (1) JP2022521528A (ru)
KR (1) KR20210132097A (ru)
CN (1) CN113677997A (ru)
AU (1) AU2020225034A1 (ru)
BR (1) BR112021016399A2 (ru)
CA (1) CA3129125A1 (ru)
EA (1) EA202192289A1 (ru)
IL (1) IL284854A (ru)
MA (1) MA55017A (ru)
MX (1) MX2021009987A (ru)
SG (1) SG11202108422XA (ru)
WO (1) WO2020169782A1 (ru)
ZA (1) ZA202106893B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022038198A1 (en) * 2020-08-19 2022-02-24 Diamidex Monosaccharide compound for the labelling of cell secretion
JP2023538615A (ja) * 2020-08-19 2023-09-08 セラオンコ 修飾単糖化合物を使用して多細胞生物由来の真核細胞を標識する方法及びキット並びにそのような細胞を含む医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004044A1 (en) * 2003-04-07 2005-01-06 Board Of Regents Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics
US8716033B2 (en) * 2006-02-10 2014-05-06 Life Technologies Corporation Oligosaccharide modification and labeling of proteins
EP3483610A1 (en) * 2009-11-09 2019-05-15 University Of Washington Center For Commercialization Functionalized chromophoric polymer dots and bioconjugates thereof
US9809560B2 (en) * 2010-08-09 2017-11-07 Albert Einstein College Of Medicine, Inc. Ligands and methods for labeling biomolecules in vivo
KR101159172B1 (ko) 2011-11-24 2012-08-07 학 성 김 Id카드이용 선후불겸용결제 방법 및 시스템
EP2617833A1 (en) 2012-01-18 2013-07-24 Centre National de la Recherche Scientifique (CNRS) A method for specifically detecting living bacteria
EP3091081A1 (en) 2015-05-04 2016-11-09 Centre National de la Recherche Scientifique (CNRS) A method for labeling specifically living microorganisms comprising the use of modified monosaccharide compounds
KR20180058737A (ko) * 2015-10-07 2018-06-01 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 암 선택적 표지화 및 표적화를 위한 트리거-활성화 대사성 당 전구체
EP3170830A1 (en) * 2015-11-17 2017-05-24 Centre National De La Recherche Scientifique New 5-azido-5-deoxy-2 :3-isopropylidene-d-arabinose compounds ; their method of manufacture and their use for the synthesis of ara-n3, kdo-n3 and 4ekdo-n3

Also Published As

Publication number Publication date
SG11202108422XA (en) 2021-09-29
MX2021009987A (es) 2021-11-04
WO2020169782A1 (en) 2020-08-27
US20220146516A1 (en) 2022-05-12
KR20210132097A (ko) 2021-11-03
IL284854A (en) 2021-08-31
EP3928097A1 (en) 2021-12-29
CA3129125A1 (en) 2020-08-27
MA55017A (fr) 2021-12-29
ZA202106893B (en) 2023-06-28
CN113677997A (zh) 2021-11-19
BR112021016399A2 (pt) 2021-10-19
JP2022521528A (ja) 2022-04-08
AU2020225034A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
SV2017005577A (es) Metodos para diagnosticar y tratar el cancer
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
MY195999A (en) Molecular Detection/Diagnosis Reagent for Tumor
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
EA201491833A1 (ru) Основанные на клетках перекрестные анализы и их применение
MX2018006781A (es) Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
CR20170104A (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
EA201390150A1 (ru) Способы выявления сигнатур заболевания или патологических состояний в текучих средах организма
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
ATE497165T1 (de) Erkennung eines erhöhten spiegels von her-2/neu- proteinen in zirkulierenden krebszellen und dessen behandlung
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
SG10201804260QA (en) Diagnostic assays and kits for detection of folate receptor 1
BR112016018205A2 (pt) métodos de tratamento de mal de alzheimer
EA201590630A1 (ru) Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2)
EA202192289A1 (ru) Способы мечения эукариотных клеток многоклеточного организма, а также лечения и/или диагностики рака с использованием модифицированных моносахаридных соединений
MX2021000295A (es) Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon.
WO2014124339A3 (en) Use of translational profiling to identify target molecules for therapeutic treatment
MX2022014741A (es) Metodos para detectar bordetella.
CY1122474T1 (el) Μεθοδος διαγνωσης νευραλγιας του τριδυμου
MX2021000882A (es) Diagnostico de la vaginosis bacteriana.
EA201991060A1 (ru) Иммунные клетки c модифицированным метаболизмом и их применение
EA201690004A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
ATE553112T1 (de) Ttk in der diagnose und als therapeutisches target bei krebs
AR104805A1 (es) Métodos y composiciones para evaluar la capacidad de respuesta de los cánceres a los inhibidores de bet